Articles
RSSPeter T. Bigelow Joins Patheon As President, North American Operations
January 20, 2010
Toronto - Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry announced recently Peter T. Bigelow has joined the company as its new President, North American Operations. Mr. Bigelow will assume responsibility for all of Patheon's commercial operating units in North America, including its Whitby, Mississauga and Burlington facilities in Canada, its Cincinnati facility in the USA, and its Caguas and Manati facilities in Puerto Rico. These six sites comprise $249M of commercial revenue.
"We are delighted to welcome Peter Bigelow to the Patheon family," said Wes Wheeler, Chief Executive Officer and President, Patheon Inc. "Peter brings nearly 30 years of operating experience to Patheon, with a wide breadth of dose forms, engineering and supply chain management. He also brings deep leadership experience to the executive ranks. We look forward to him joining us and introducing him to our growing list of clients"
Mr. Bigelow most recently served as Senior Vice President at Wyeth Pharmaceuticals, where he had responsibility for Wyeth's global consumer healthcare product manufacturing and oversight of Wyeth's operations in Latin America. He joined Wyeth in 1995 and in his 14 years had several executive posts spanning the breadth of pharmaceutical manufacturing and technical operations. Prior to joining Wyeth, Peter spent 13 years with Smithkline Beecham (now GlaxoSmithkline) in a variety of Engineering and Operations roles. He holds a BS in Mechanical Engineering from Villanova University and an MBA from Philadelphia University.
About Patheon
Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon, with its integrated development and manufacturing network of 11 facilities and six development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world,
SOURCE: Patheon Inc.
